<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:department>Cancer Sciences</gtr:department><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/7B4D4F63-62DD-488C-AAA7-F3E1683C1D88"><gtr:id>7B4D4F63-62DD-488C-AAA7-F3E1683C1D88</gtr:id><gtr:firstName>Alan</gtr:firstName><gtr:surname>Rickinson</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/9935876F-FF1E-4555-A6DD-3818DEF017BC"><gtr:id>9935876F-FF1E-4555-A6DD-3818DEF017BC</gtr:id><gtr:firstName>Paul</gtr:firstName><gtr:surname>Moss</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/440DF539-45E2-492D-968F-DA8B55D36568"><gtr:id>440DF539-45E2-492D-968F-DA8B55D36568</gtr:id><gtr:firstName>Martin</gtr:firstName><gtr:surname>Rowe</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0901755"><gtr:id>45669CC1-4294-480B-A186-406EE56C51F6</gtr:id><gtr:title>Cellular immunity to herpesvirus infections: studies with Epstein-Barr virus (EBV) and human cytomegalovirus (CMV)</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0901755</gtr:grantReference><gtr:abstractText>Human herpes viruses are a group of eight related viruses which cause a range of diseases such as glandular fever, chicken pox and some cancers. One remarkable feature is that they are never eradicated from our bodies after infection but persist for many decades. However, these ?chronic infections? may be associated with clinical complications arising from virus-induced distortion of the immune system. 
Over many years we have studied the immune response to two of these viruses, Epstein Barr Virus (EBV) and Cytomegalovirus (CMV, which infect the vast majority of the human population. We have studied the immune response that develops against the viruses both in healthy donors and those who are immune-suppressed.
We now propose to continue our work in three main areas. 
Firstly, we will study how a major component of the immune response, T cells, control the viruses. We will focus on which viral proteins are ?seen? by the T cells and how this is related to proteins the virus makes to evade immunity. We will determine which responses survive over time and the mechanisms behind this. We will also study how immunity is maintained in elderly individuals and which factors underlie the potentially damaging expansion of the immune response in some elderly people.
Secondly we will make a detailed study of the proteins that the virus makes in order to suppress the immune response such that it can survive. This is important to understand both the profile of immune response that is observed and also how we may improve this in the future.
Thirdly, we will study the balance between the virus and the immune response, as seen in healthy people and in patients, to understand the effect of these viruses on the general immune function of the population. We will determine what level of virus different people are carrying, whether the level is stable over rtime and how this determines the nature of the immune response. We will study how single infection with either EBV or CMV, or dual infection with both viruses, influences the immune system, and how anti-viral drugs might improve immune function.
Overall this work should provide the most detailed analysis of the interaction between our immune systems and herpesviruses. EBV and CMV are increasingly recognised as major global pathogens and our programme is an important opportunity to determine the factors and mechanisms that contribute to viral disease.</gtr:abstractText><gtr:technicalSummary>Our work focuses on two human herpesviruses, Epstein-Barr virus (EBV) and cytomegalovirus (CMV), which elicit strong T cell-mediated responses in the immunocompetent host but are life-threatening in immunocompromised settings. We propose three areas of work on:-.

(i) Immunodominance and the evolution of viral immune responses : we shall study the different hierarchy of CD8 immunodominance among immediate early (IE), early (E) and late (L) antigens of the EBV lytic cycle (IE E L) with that found for CMV, where strong responses to IE, E and L antigens exist. Experiments, involving both infectious mononucleosis (IM) and X-linked lymphoproliferative disease (XLP) patients, will test the hypothesis that EBV-induced CD8 responses are directly primed by virus-infected B cells. We shall also compare the CD8 response to known immunodominant CMV epitopes with that to a range of new, subdominant epitopes, looking for inter-epitope differences in phenotype and age-dependent response inflation. Parallel work will study the size and kinetics of CD4 responses to newly-defined EBV and CMV epitopes in primary and persistent infection and ask whether, superimposed on the cross-primed response, there is enhanced reactivity to antigens which naturally access the MHC II pathway in lytically-infected cells.

(ii) Immune evasion : here we extend the study of CD8 immune evasion by EBV, using gene-deleted viruses to ask what influence the three EBV lytic cycle proteins with known evasion function (BNLF2a, BGLF5 and BILF1) have upon antigen presentation in the natural context of the lytically-infected cell, in particular how their separate functions complement one another at different stages of lytic cycle. In parallel, we shall use the methods that have identified natural killer (NK) evasion functions in CMV to screen the whole EBV lytic gene set for evidence of similar NK evasion effects, and use newly-developed experimental approaches to examine the functional importance of four lytic cycle proteins (BZLF1, BGLF5, BCRF1 and gp42) which are candidate effectors of CD4 immune evasion. 

(iii) Virus-host balance in the immunocompetent and immunosuppressed : here we analyse virus-host interactions at the tissue level, looking at the homing and intra-tissue localisation of virus-specific T cells, and at the whole organism level through cross-sectional and prospective studies on newly-established cohorts of young immunocompetent, elderly and patient groups. There we focus on issues of response magnitude in relation to latent and lytic virus load, the antigen-dependence of response persistence, and the effect of virus carriage on overall composition of the T cell pool.</gtr:technicalSummary><gtr:fund><gtr:end>2015-08-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2010-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>2066640</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Medical Research Council (MRC)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>MRC Centre for Immune Regulation</gtr:department><gtr:description>MRC Centre For Immune Regulation</gtr:description><gtr:id>7AF48828-3EE9-43DC-B026-3D9EDBEBEBD7</gtr:id><gtr:impact>Studentships and papers</gtr:impact><gtr:partnerContribution>Studentships and facilities</gtr:partnerContribution><gtr:piContribution>Theme Lead Cellular immunity to viral infections</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Media enquiries</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>4777CA54-5D6C-4B40-9C9A-E6E2F686B9FB</gtr:id><gtr:impact>Several press articles were published.

This activity increased public awareness of immune approaches to cancer therapy.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2011,2012,2013,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Charity fund-raisers, Birmingham</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>B09B0891-11AC-479E-BF94-DA9BBA25E9DF</gtr:id><gtr:impact>Over 100 members of the public visited the research laboratories, were given a presentation of the work performed, and taken for a guided tour of the laboratories to observe practical demonstrations.

This activity increased the public profile of the MRC Centre and the University of Birmingham as a research-based institution.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2010,2011,2012,2013,2014</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Prospective blood samples from infectious mononucleosis patients and large numbers of medical school entrants, for virologic/immunologic studies.</gtr:description><gtr:id>AA846D8E-6A91-4AC5-8C09-4850011B24E6</gtr:id><gtr:impact>This data will be made freely available to other researchers within/beyond the University of Birmingham after journal publication.</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Prospective blood and serum samples</gtr:title><gtr:type>Database/Collection of Data/Biological Samples</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/22F9B87D-D28B-436C-A4F2-C13DE3BEA590"><gtr:id>22F9B87D-D28B-436C-A4F2-C13DE3BEA590</gtr:id><gtr:title>Renal function in patients undergoing transplantation for nonalcoholic steatohepatitis cirrhosis: time to reconsider immunosuppression regimens?</gtr:title><gtr:parentPublicationTitle>Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/99dcc6cdf30cefe3cc91c16b6c27e97c"><gtr:id>99dcc6cdf30cefe3cc91c16b6c27e97c</gtr:id><gtr:otherNames>Houlihan DD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1527-6465</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/24FF5B8E-5093-4DA9-B9F8-06E56BCE9959"><gtr:id>24FF5B8E-5093-4DA9-B9F8-06E56BCE9959</gtr:id><gtr:title>CD8+ T cell responses to lytic EBV infection: late antigen specificities as subdominant components of the total response.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/f2b9d77d065cedd6a178e9f762819463"><gtr:id>f2b9d77d065cedd6a178e9f762819463</gtr:id><gtr:otherNames>Abbott RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/68E33BB0-C164-40D2-B7EA-BF589085B3B6"><gtr:id>68E33BB0-C164-40D2-B7EA-BF589085B3B6</gtr:id><gtr:title>Epstein-Barr virus evades CD4+ T cell responses in lytic cycle through BZLF1-mediated downregulation of CD74 and the cooperation of vBcl-2.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/72d96a4bcbdce942d350d62e762139ba"><gtr:id>72d96a4bcbdce942d350d62e762139ba</gtr:id><gtr:otherNames>Zuo J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/19A0D655-9F6B-45DB-86D5-4BC6D088DFF3"><gtr:id>19A0D655-9F6B-45DB-86D5-4BC6D088DFF3</gtr:id><gtr:title>MHC II tetramers visualize human CD4+ T cell responses to Epstein-Barr virus infection and demonstrate atypical kinetics of the nuclear antigen EBNA1 response.</gtr:title><gtr:parentPublicationTitle>The Journal of experimental medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/dc17541961a574382f3fd6e17b82a408"><gtr:id>dc17541961a574382f3fd6e17b82a408</gtr:id><gtr:otherNames>Long HM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-1007</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DAFB6304-9920-48FD-B609-7805C45CA85C"><gtr:id>DAFB6304-9920-48FD-B609-7805C45CA85C</gtr:id><gtr:title>Cytotoxic CD4+ T cell responses to EBV contrast with CD8 responses in breadth of lytic cycle antigen choice and in lytic cycle recognition.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/dc17541961a574382f3fd6e17b82a408"><gtr:id>dc17541961a574382f3fd6e17b82a408</gtr:id><gtr:otherNames>Long HM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/CA052550-F7B0-4223-85F4-6633F5838442"><gtr:id>CA052550-F7B0-4223-85F4-6633F5838442</gtr:id><gtr:title>A mutation in X-linked inhibitor of apoptosis (G466X) leads to memory inflation of Epstein-Barr virus-specific T cells.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/dd6d6d928cadfcde3ff7e68c18ceb27d"><gtr:id>dd6d6d928cadfcde3ff7e68c18ceb27d</gtr:id><gtr:otherNames>Lopez-Granados E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0009-9104</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0474859C-122A-457C-9C71-060646C6EB51"><gtr:id>0474859C-122A-457C-9C71-060646C6EB51</gtr:id><gtr:title>Herpesviruses placating the unwilling host: manipulation of the MHC class II antigen presentation pathway.</gtr:title><gtr:parentPublicationTitle>Viruses</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/72d96a4bcbdce942d350d62e762139ba"><gtr:id>72d96a4bcbdce942d350d62e762139ba</gtr:id><gtr:otherNames>Zuo J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1999-4915</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9D1A0686-AFD2-4275-9FD9-3254245676C5"><gtr:id>9D1A0686-AFD2-4275-9FD9-3254245676C5</gtr:id><gtr:title>Early T Cell Recognition of B Cells following Epstein-Barr Virus Infection: Identifying Potential Targets for Prophylactic Vaccination.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6a0f4e705a3dff799b6610affff330a6"><gtr:id>6a0f4e705a3dff799b6610affff330a6</gtr:id><gtr:otherNames>Brooks JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4FD9509F-4A21-4275-BED6-1E65026F9D68"><gtr:id>4FD9509F-4A21-4275-BED6-1E65026F9D68</gtr:id><gtr:title>ATM germline heterozygosity does not play a role in chronic lymphocytic leukemia initiation but influences rapid disease progression through loss of the remaining ATM allele.</gtr:title><gtr:parentPublicationTitle>Haematologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d5c4afad9ed63e2ce14e6955cc09639a"><gtr:id>d5c4afad9ed63e2ce14e6955cc09639a</gtr:id><gtr:otherNames>Skowronska A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0390-6078</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9DE6019F-2052-4F5E-B18D-184F661F00E7"><gtr:id>9DE6019F-2052-4F5E-B18D-184F661F00E7</gtr:id><gtr:title>Immune defence against EBV and EBV-associated disease.</gtr:title><gtr:parentPublicationTitle>Current opinion in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/dc17541961a574382f3fd6e17b82a408"><gtr:id>dc17541961a574382f3fd6e17b82a408</gtr:id><gtr:otherNames>Long HM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0952-7915</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B614E4F7-79E0-4B7D-A2F6-7CF8F12B2D1D"><gtr:id>B614E4F7-79E0-4B7D-A2F6-7CF8F12B2D1D</gtr:id><gtr:title>The Cellular Localization of Human Cytomegalovirus Glycoprotein Expression Greatly Influences the Frequency and Functional Phenotype of Specific CD4+ T Cell Responses.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0210c8fb0cdd215c901a1cc65ae5b66a"><gtr:id>0210c8fb0cdd215c901a1cc65ae5b66a</gtr:id><gtr:otherNames>Pachnio A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/935B6A91-C3D6-4650-A950-3C5A90441F34"><gtr:id>935B6A91-C3D6-4650-A950-3C5A90441F34</gtr:id><gtr:title>KIR and HLA-C interactions promote differential dendritic cell maturation and is a major determinant of graft failure following kidney transplantation.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/eb0524308690bac01d80d7c79d89341a"><gtr:id>eb0524308690bac01d80d7c79d89341a</gtr:id><gtr:otherNames>Hanvesakul R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/7F706FBB-1ED1-4ED3-B1CB-53BF26DA4BD4"><gtr:id>7F706FBB-1ED1-4ED3-B1CB-53BF26DA4BD4</gtr:id><gtr:title>The role of tetraspanin CD63 in antigen presentation via MHC class II.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/5f994e37a1370e2c93d16c9c21badff6"><gtr:id>5f994e37a1370e2c93d16c9c21badff6</gtr:id><gtr:otherNames>Petersen SH</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2840D129-E364-4DFC-B50A-19B079FB45CC"><gtr:id>2840D129-E364-4DFC-B50A-19B079FB45CC</gtr:id><gtr:title>Epstein-Barr virus latent gene sequences as geographical markers of viral origin: unique EBNA3 gene signatures identify Japanese viruses as distinct members of the Asian virus family.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/880b5685a8e5b4a1a1796c6c78a1ba79"><gtr:id>880b5685a8e5b4a1a1796c6c78a1ba79</gtr:id><gtr:otherNames>Sawada A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D3ACA5D7-72B3-4906-B17F-FBF5D29289CB"><gtr:id>D3ACA5D7-72B3-4906-B17F-FBF5D29289CB</gtr:id><gtr:title>The Missing Link in Epstein-Barr Virus Immune Evasion: the BDLF3 Gene Induces Ubiquitination and Downregulation of Major Histocompatibility Complex Class I (MHC-I) and MHC-II.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/879a5efbdff332a2d08dfb2e2258115b"><gtr:id>879a5efbdff332a2d08dfb2e2258115b</gtr:id><gtr:otherNames>Quinn LL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1FE30ED6-3C1C-43B9-AC90-80C4B5B61BA6"><gtr:id>1FE30ED6-3C1C-43B9-AC90-80C4B5B61BA6</gtr:id><gtr:title>Protease inhibitors for treatment of genotype 1 hepatitis C virus infection.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/68859e2678f8b3f51bdc173b90573c7b"><gtr:id>68859e2678f8b3f51bdc173b90573c7b</gtr:id><gtr:otherNames>Rowe IA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D5EB5FD9-77CF-4568-8281-47ED93135E34"><gtr:id>D5EB5FD9-77CF-4568-8281-47ED93135E34</gtr:id><gtr:title>Cellular immune controls over Epstein-Barr virus infection: new lessons from the clinic and the laboratory.</gtr:title><gtr:parentPublicationTitle>Trends in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c66167e65ce63187dee51e87aec34d23"><gtr:id>c66167e65ce63187dee51e87aec34d23</gtr:id><gtr:otherNames>Rickinson AB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1471-4906</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/ABEDB44D-BC8B-44CC-941B-EF7F2F2D698F"><gtr:id>ABEDB44D-BC8B-44CC-941B-EF7F2F2D698F</gtr:id><gtr:title>Dominant responses with conservation of T-cell receptor usage in the CD8+ T-cell recognition of a cancer testis antigen peptide presented through HLA-Cw7 in patients with multiple myeloma.</gtr:title><gtr:parentPublicationTitle>Cancer immunology, immunotherapy : CII</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4d79d6bb31b113551ddb534931c5a620"><gtr:id>4d79d6bb31b113551ddb534931c5a620</gtr:id><gtr:otherNames>Goodyear OC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0340-7004</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8EDBA709-8706-4549-9D27-92E6BA04DED0"><gtr:id>8EDBA709-8706-4549-9D27-92E6BA04DED0</gtr:id><gtr:title>Characterization of CMV-specific CD4+ T-cell reconstitution following stem cell transplantation through the use of HLA Class II-peptide tetramers identifies patients at high risk of recurrent CMV reactivation.</gtr:title><gtr:parentPublicationTitle>Haematologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b95d132b4f52014b4f01ba205a8aaa8c"><gtr:id>b95d132b4f52014b4f01ba205a8aaa8c</gtr:id><gtr:otherNames>Raeiszadeh M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0390-6078</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AB5E730E-C361-4150-80BE-608E9A563A87"><gtr:id>AB5E730E-C361-4150-80BE-608E9A563A87</gtr:id><gtr:title>Induction of the Lytic Cycle Sensitizes Epstein-Barr Virus-Infected B Cells to NK Cell Killing That Is Counteracted by Virus-Mediated NK Cell Evasion Mechanisms in the Late Lytic Cycle.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8105854f6c79083a9dd41b0f14d6395f"><gtr:id>8105854f6c79083a9dd41b0f14d6395f</gtr:id><gtr:otherNames>Williams LR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0994E86B-7D3B-4C02-AB40-B178E795AA3B"><gtr:id>0994E86B-7D3B-4C02-AB40-B178E795AA3B</gtr:id><gtr:title>CD4+CD28- T cell expansion in granulomatosis with polyangiitis (Wegener's) is driven by latent cytomegalovirus infection and is associated with an increased risk of infection and mortality.</gtr:title><gtr:parentPublicationTitle>Arthritis and rheumatism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c6034b3f3e7c6b7a1167bd45177ae553"><gtr:id>c6034b3f3e7c6b7a1167bd45177ae553</gtr:id><gtr:otherNames>Morgan MD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0004-3591</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/30E3AC3B-DEA9-4A54-A5FD-F6D9B8E7ADC3"><gtr:id>30E3AC3B-DEA9-4A54-A5FD-F6D9B8E7ADC3</gtr:id><gtr:title>Kaposi's sarcoma-associated herpesvirus-encoded viral IRF3 modulates major histocompatibility complex class II (MHC-II) antigen presentation through MHC-II transactivator-dependent and -independent mechanisms: implications for oncogenesis.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/72d96a4bcbdce942d350d62e762139ba"><gtr:id>72d96a4bcbdce942d350d62e762139ba</gtr:id><gtr:otherNames>Zuo J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/90E67EB6-19CD-40B8-8E99-D50D3AB16F57"><gtr:id>90E67EB6-19CD-40B8-8E99-D50D3AB16F57</gtr:id><gtr:title>Epstein-Barr virus BamHI W repeat number limits EBNA2/EBNA-LP coexpression in newly infected B cells and the efficiency of B-cell transformation: a rationale for the multiple W repeats in wild-type virus strains.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ea3889765cd3c0bc1b940f193d4ea99e"><gtr:id>ea3889765cd3c0bc1b940f193d4ea99e</gtr:id><gtr:otherNames>Tierney RJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2E60149B-8682-426B-931A-375A25323F45"><gtr:id>2E60149B-8682-426B-931A-375A25323F45</gtr:id><gtr:title>Acyclovir Therapy Reduces the CD4+ T Cell Response against the Immunodominant pp65 Protein from Cytomegalovirus in Immune Competent Individuals.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0210c8fb0cdd215c901a1cc65ae5b66a"><gtr:id>0210c8fb0cdd215c901a1cc65ae5b66a</gtr:id><gtr:otherNames>Pachnio A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E6AA440E-C617-4355-A196-B0D9A135BD1C"><gtr:id>E6AA440E-C617-4355-A196-B0D9A135BD1C</gtr:id><gtr:title>Cytomegalovirus sero positivity dramatically alters the maternal CD8+ T cell repertoire and leads to the accumulation of highly differentiated memory cells during human pregnancy.</gtr:title><gtr:parentPublicationTitle>Human reproduction (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2c8d213937d9bd1b0048c2eba50d0098"><gtr:id>2c8d213937d9bd1b0048c2eba50d0098</gtr:id><gtr:otherNames>Lissauer D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0268-1161</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B6E37FE4-5551-4342-9DB4-2698139D1A23"><gtr:id>B6E37FE4-5551-4342-9DB4-2698139D1A23</gtr:id><gtr:title>Cooperation between Epstein-Barr virus immune evasion proteins spreads protection from CD8+ T cell recognition across all three phases of the lytic cycle.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/879a5efbdff332a2d08dfb2e2258115b"><gtr:id>879a5efbdff332a2d08dfb2e2258115b</gtr:id><gtr:otherNames>Quinn LL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E9576379-E16B-4218-9C7E-CD340576F483"><gtr:id>E9576379-E16B-4218-9C7E-CD340576F483</gtr:id><gtr:title>Chronic lymphocytic leukaemia cells drive the global CD4+ T cell repertoire towards a regulatory phenotype and leads to the accumulation of CD4+ forkhead box P3+ T cells.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/59bd46df237acf88f505ec2459749fe5"><gtr:id>59bd46df237acf88f505ec2459749fe5</gtr:id><gtr:otherNames>Piper KP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0009-9104</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0901755</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>